Angiomax bivalirudin regulatory update

FDA approved an sNDA for Angiomax for use in patients with or at risk of heparin-induced thrombosis syndrome (HITTS) and thrombocytopenia (HIT) and undergoing percutaneous coronary intervention (PCI)....